January 9, 2013 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , a provider of unique trading technologies, released a report on Tuesday, January 8th 2013 stating that Generex Biotechnology Corp (NASDAQ:GNBT) was expected to go Up due to the Bullish conditions presented in the following report. Click here to view the BUYINS.NET report: http://www.buyins.net/releases/?sym=gnbt&id=339458
At the time this story was written, Generex Biotechnology Corp (NASDAQ:GNBT) is Up By $0.01 (12.20%) since the BUYINS.NET report was released.
The movement of stock prices in the days and weeks leading to and following specific fundamental or technical events may follow a predictable pattern. Many companies stock price histories show random or unpredictable movements around certain events. But some seem to repeat the same pattern quarter after quarter, year after year. We use powerful computers to uncover those events and correlations to generate predictions with high probabilities of generating very specific returns within very specific time periods.
The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php
Generex Biotechnology Corp (NASDAQ:GNBT) - Generex Biotechnology Corporation, a development stage company, engages in the research, development, and commercialization of drug delivery systems and technologies for metabolic and immunological diseases. The company focuses on its proprietary technology for the administration of formulations of large molecule drugs to the oral cavity using a hand-held aerosol applicator. Its products include Generex Oral-lyn, an insulin formulation administered as a fine spray into the oral cavity using RapidMist hand-held aerosol spray applicator, for the treatment of Type 1 and Type 2 diabetes; over-the-counter glucose sprays, including Glucose RapidSpray that delivers a fat-free low-calorie glucose formulation directly into the mouth; and MetControl, a Metformin medicinal chewing gum product. The company also engages in the research and development of technologies and immunomedicines for the treatment of malignant, infectious, autoimmune, and allergic diseases. It develops immunotherapeutic vaccine AE37 that is under Phase II clinical trial for patients with HER-2/neu positive breast cancer. The company sells its products through retail stores and independent pharmacies primarily in the United States and Canada. Generex Biotechnology Corporation was founded in 1983 and is based in Toronto, Canada..
About BUYINS.NET
BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:
REGULATORY & COMPLIANCE NEWS
Friction Factor market-maker surveillance system tracking Level II market-makers in all stocks to determine Price Friction and compliance with new "Fair Market-Making Requirements"
RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO
INVESTMENTS & TRADING
SqueezeTrigger -- 30 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.
Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.
Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.
Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.
Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.
GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.
DISCLAIMER:
BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies specifically for this report, but may have been compensated up to $1,200 per month in the past for unrelated data or report services. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.
Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net
